We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

Noradrenergic and specific serotonergic antidepressants

    Emma Heck

    Emma Heck is an undergraduate student at Queen’s University in Kingston, Ontario, Canada. She is working towards her Bachelor of Commerce while also taking a mixture of science courses.

    Search for more papers by this author

    &
    Glenda MacQueen

    Glenda MacQueen is Professor and Head of the Department of Psychiatry, Faculty of Medicine, University of Calgary, Alberta, Canada. She is a member of the Hotchkiss Brain Institute. She is also Zone Clinical Department Head and Medical Lead for Addictions and Mental Health in the Calgary Health Zone, Alberta Health Services. She is a clinical editor of the Current Medical Literature Psychiatry series and is an associate editor of the Canadian Journal of Psychiatry. Her clinical and research interests are in mood disorders.

    Search for more papers by this author

    Published Online:27 Jun 2012https://doi.org/10.2217/ebo.11.227
    Abstract:

    Mirtazapine is a novel antidepressant with a unique pharmacological profile, which is approved in many countries for the treatment of depression. It belongs to the class of noradrenergic and specific serotonergic antidepressants, and numerous studies have shown that it demonstrates a positive tolerability and safety profile. Mirtazapine has proven to be effective in the treatment of depression and may have a role in the treatment of other disorders.

    References

    • 1  Fawcett J , Barkin R . Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression . J. Affect. Disord. 51 , 267 – 285 (1998) .
      Medline CASGoogle Scholar
    • 2  Croom K , Perry C , Plosker G . Mirtazapine: a review of its use in major depression and other psychiatric disorders . CNS Drugs 23 (5) , 427 – 452 (2009) .
      Medline CASGoogle Scholar
    • 3  Brown University psychopharmacology update. Your Medication Information . Mirtazapine (2008) .
      Google Scholar
    • 4  Navarro V . Improving medication compliance in patients with depression: use of orodispersible tablets . Adv. Ther. 27 (11) , 785 – 795 (2010) .
      Medline CASGoogle Scholar
    • 5  Watanabe N , Omori IM , Nakagawa A et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression . CNS Drugs 24 (1) , 35 – 53 (2010) .
      Medline CASGoogle Scholar
    • 6  Serretti A , Mandelli L . Antidepressants and body weight: a comprehensive review and meta-analysis . J. Clin. Psychiatry 71 (10) , 1259 – 1272 (2010) .
      MedlineGoogle Scholar
    • 7  Montgomery SA . Safety of mirtazapine: a review . Int. Clin. Psychopharmacol. 10 (Suppl.4) , 37 – 45 (1995) .
      MedlineGoogle Scholar
    • 8  Hawton K , Bergen H , Simkin S et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose . Br. J. Psychiat. 196 , 354 – 358 (2010) .
      MedlineGoogle Scholar
    • 9  Watanabe N , Omori I , Nakagawa A et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis . J. Clin. Psychiat. 69 , 1404 – 1415 (2008) .
      Medline CASGoogle Scholar
    • 10  Cipriani A , Furukawa T , Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis . Lancet 373 , 746 – 758 (2009) .
      Medline CASGoogle Scholar
    • 11  Blier P , Gobbi G , Turcotte JE et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation . Eur. Neuropsychopharm. 19 (7) , 457 – 465 (2009) .
      Medline CASGoogle Scholar
    • 12  Papakostas G . Managing partial or nonresponse: switching, augmentation and combination strategies for major depressive disorder . J. Clin. Psychiatry 70 (Suppl.6) , 16 – 25 (2009) .
      Medline CASGoogle Scholar
    • 13  Blier P , Ward HE , Tremblay P et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study . Am. J. Psychiatry 167 (3) , 281 – 288 (2010) .
      MedlineGoogle Scholar
    • 14  Rush AJ , Trivedi M , Stewart J et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study . Am. J. Psychiatry 168 (7) , 1 – 13 (2011) .
      MedlineGoogle Scholar
    • 15  Marshall N , Yee B , Desai A et al. Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea . Sleep 31 (6) , 824 – 831 (2008) .
      MedlineGoogle Scholar
    • 16  Becker P . Treatment of sleep dysfunction and psychiatric disorders . Curr. Treat. Options Neurol. 8 , 367 – 375 (2006) .
      MedlineGoogle Scholar
    • 17  Stenberg JH , Terevnikov V , Joffe M et al. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia . Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (4) , 1080 – 1086 (2011) .
      Medline CASGoogle Scholar
    • 18  Atmaca M , Korkmaz S , Topuz M et al. Mirtazapine augmentation for selective serotonin reuptake inhibitor-induced sexual dysfunction: a retrospective investigation . Psychiatry Investig. 8 , 55 – 57 (2011) .
      Medline CASGoogle Scholar
    • 19  San L , Arranz B . Mirtazapine: only for depression? Acta Neuropsychiatrica 18 , 130 – 143 (2006) .
      MedlineGoogle Scholar
    • 20  Terevnikov V , Stenberg JH , Tiihonen J et al. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase . Hum. Psychopharmacol. doi:10.1002/hup.1189 (2011) (Epub ahead of print) .
      MedlineGoogle Scholar
    • 21  Hazell P . Depression in children and adolescents . Clin. Evidence 7 , 307 – 313 (2002) .
      MedlineGoogle Scholar
    • 22  Timmer C , Ad Sitsen JM , Delbressine L . Clinical pharmacokinetics of mirtazapine . Clin. Pharmacokinet. 38 (6) , 461 – 474 (2000) .
      Medline CASGoogle Scholar
    • 23  Noe K , Locke D , Sirven J . Treatment of depression in patients with epilepsy . Curr. Treat. Options Neurol. 13 (4) , 371 – 391 (2011) .
      MedlineGoogle Scholar
    • 24  Klier CM , Mossaheb N , Lee A et al. Mirtazapine and breastfeeding: maternal and infant plasma levels . Am. J. Psychiatry 164 , 348 – 349 (2007) .
      MedlineGoogle Scholar
    • 25  Schatzberg AF , Kremer C , Rodrigues HE et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients . Am. J. Geriatr. Psychiatry 10 (5) , 541 – 550 (2002) .
      MedlineGoogle Scholar

    Website